AbbVie (NYSE: ABBV) and (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while Pfizer's coronavirus vaccine generated peak sales of $37 billion -- in 2022, in both cases. With results like those, you might expect their stocks to still be soaring, but they aren't.

Instead, AbbVie and Pfizer shares have dropped by double-digit percentages this year, and for reasons that are understandable. The companies have something in common. Sales of both of their top-selling products are on the decline in a big way. Humira has lost exclusivity, and demand for Pfizer's coronavirus vaccine is declining now that we have exited the health-crisis stage of the pandemic. But does this mean you should follow the crowd and sell shares of these companies?

Image source: Getty Images.

Continue reading

Source Fool.com